Search

Your search keyword '"Wheatley, Keith"' showing total 933 results
Start Over Author "Wheatley, Keith"
933 results on '"Wheatley, Keith"'

3. Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Author

Chaganti, Sridhar, Maycock, Shanna, McIlroy, Graham, Jackson, Aimee, Bishop, Rebecca, Johnson, Sarah, Kanfer, Edward, Kassam, Shireen, Cwynarski, Kate, Wrench, David, Arumainathan, Arvind, Fox, Christopher P., Johnson, Rod, McKay, Pam, Paneesha, Shankara, Rowntree, Clare, Balotis, Constantine, Collins, Graham P., Davies, Andrew, Wright, Josh, Burns, Sarah, Laurence, Arian, Wheatley, Keith, and Menne, Tobias

Published
2024
Full Text
View/download PDF

4. ACRS Chapter reports

Author

Chalmers, Eric, Wheatley, Keith, MacKenzie, Jamie, Blake, Phil, McRae, Duncan, Prabhakharan, Prasannah, and Williams, Teresa

Published
2021

5. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial

Author

Alexander, Sarah, Aupérin, Anne, Bomken, Simon, Csóka, Monika, Kazanowska, Bernarda, Chiang, Alan K, Andres, Mara, Uyttebroeck, Anne, Burke, G A Amos, Zsiros, József, Pillon, Marta, Bollard, Catherine M, Mussolin, Lara, Verdu-Amoros, Jaime, Neven, Bénédicte, Barkauskas, Donald A, Wheatley, Keith, Patte, Catherine, Gross, Thomas G, and Minard-Colin, Véronique

Published
2023
Full Text
View/download PDF

6. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.

Author

Dirksen, Uta, Brennan, Bernadette, Le Deley, Marie-Cécile, Cozic, Nathalie, van den Berg, Henk, Bhadri, Vivek, Brichard, Bénédicte, Claude, Line, Craft, Alan, Amler, Susanne, Gaspar, Natalie, Gelderblom, Hans, Goldsby, Robert, Gorlick, Richard, Grier, Holcombe E, Guinbretiere, Jean-Marc, Hauser, Peter, Hjorth, Lars, Janeway, Katherine, Juergens, Heribert, Judson, Ian, Krailo, Mark, Kruseova, Jarmila, Kuehne, Thomas, Ladenstein, Ruth, Lervat, Cyril, Lessnick, Stephen L, Lewis, Ian, Linassier, Claude, Marec-Berard, Perrine, Marina, Neyssa, Morland, Bruce, Pacquement, Hélène, Paulussen, Michael, Randall, R Lor, Ranft, Andreas, Le Teuff, Gwénaël, Wheatley, Keith, Whelan, Jeremy, Womer, Richard, Oberlin, Odile, Hawkins, Douglas S, and Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators

Subjects
Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators, Humans, Bone Neoplasms, Lung Neoplasms, Neoplasm Recurrence, Local, Disease Progression, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy, Radiotherapy, Adjuvant, Pneumonectomy, Hematopoietic Stem Cell Transplantation, Transplantation, Autologous, Risk Assessment, Risk Factors, Time Factors, Adolescent, Adult, Middle Aged, Child, Child, Preschool, Infant, Europe, Female, Male, Young Adult, Sarcoma, Ewing, Progression-Free Survival, Lung, Stem Cell Research, Cancer, Pediatric, Rare Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy with WLI in Ewing sarcoma (ES) presenting with pulmonary and/or pleural metastases.MethodsFrom 2000 to 2015, we enrolled patients younger than 50 years of age with newly diagnosed ES and with only pulmonary or pleural metastases. Patients received chemotherapy with six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) and one course of vincristine, dactinomycin, and ifosfamide (VAI) before either BuMel or seven courses of VAI and WLI (VAI plus WLI) by randomized assignment. The analysis was conducted as intention to treat. The estimates of the hazard ratio (HR), 95% CI, and P value were corrected for the three previous interim analyses by the inverse normal method.ResultsOf 543 potentially eligible patients, 287 were randomly assigned to VAI plus WLI (n = 143) or BuMel (n = 144). Selected patients requiring radiotherapy to an axial primary site were excluded from randomization to avoid excess organ toxicity from interaction between radiotherapy and busulfan. Median follow-up was 8.1 years. We did not observe any significant difference in survival outcomes between treatment groups. Event-free survival was 50.6% versus 56.6% at 3 years and 43.1% versus 52.9% at 8 years, for VAI plus WLI and BuMel patients, respectively, resulting in an HR of 0.79 (95% CI, 0.56 to 1.10; P = .16). For overall survival, the HR was 1.00 (95% CI, 0.70 to 1.44; P = .99). Four patients died as a result of BuMel-related toxicity, and none died after VAI plus WLI. Significantly more patients in the BuMel arm experienced severe acute toxicities than in the VAI plus WLI arm.ConclusionIn ES with pulmonary or pleural metastases, there is no clear benefit from BuMel compared with conventional VAI plus WLI.

Published
2019

9. Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Author

Chisholm, Julia, primary, Mandeville, Henry, additional, Adams, Madeleine, additional, Minard-Collin, Veronique, additional, Rogers, Timothy, additional, Kelsey, Anna, additional, Shipley, Janet, additional, van Rijn, Rick R., additional, de Vries, Isabelle, additional, van Ewijk, Roelof, additional, de Keizer, Bart, additional, Gatz, Susanne A., additional, Casanova, Michela, additional, Hjalgrim, Lisa Lyngsie, additional, Firth, Charlotte, additional, Wheatley, Keith, additional, Kearns, Pamela, additional, Liu, Wenyu, additional, Kirkham, Amanda, additional, Rees, Helen, additional, Bisogno, Gianni, additional, Wasti, Ajla, additional, Wakeling, Sara, additional, Heenen, Delphine, additional, Tweddle, Deborah A., additional, Merks, Johannes H. M., additional, and Jenney, Meriel, additional

Published
2024
Full Text
View/download PDF

10. PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults

Author

Fenwick, Nicola, primary, Weston, Rebekah, additional, Wheatley, Keith, additional, Hodgson, Jodie, additional, Marshall, Lynley, additional, Elliott, Martin, additional, Makin, Guy, additional, Ng, Antony, additional, Brennan, Bernadette, additional, Lowis, Stephen, additional, Adamski, Jenny, additional, Kilday, John Paul, additional, Cox, Rachel, additional, Gattens, Mike, additional, Moore, Andrew, additional, Trahair, Toby, additional, Ronghe, Milind, additional, Campbell, Martin, additional, Campbell, Helen, additional, Williams, Molly W., additional, Kirby, Maria, additional, Van Eijkelenburg, Natasha, additional, Keely, Jennifer, additional, Scarpa, Ugo, additional, Stavrou, Victoria, additional, Fultang, Livingstone, additional, Booth, Sarah, additional, Cheng, Paul, additional, De Santo, Carmela, additional, and Mussai, Francis, additional

Published
2024
Full Text
View/download PDF

12. Longer-term efficiency and safety of increasing the frequency of whole blood donation (INTERVAL): extension study of a randomised trial of 20 757 blood donors

Author

Kaptoge, Stephen, Di Angelantonio, Emanuele, Moore, Carmel, Walker, Matthew, Armitage, Jane, Ouwehand, Willem H, Roberts, David J, Danesh, John, Thompson, Simon G, Donovan, Jenny, Ford, Ian, Henry, Rachel, Hunt, Beverley J, le Huray, Bridget, Mehenny, Susan, Miflin, Gail, Green, Jane, Stredder, Mike, Watkins, Nicholas A, McDermott, Alan, Ronaldson, Clive, Thomson, Claire, Tolkien, Zoe, Williamson, Lorna, Allan, David, Sambrook, Jennifer, Hammerton, Tracey, Bruce, David, Choudry, Fizzah, Ghvaert, Cedric, Jonston, Kirstie, Kelly, Anne, King, Andrew, Mo, Alfred, Page, Lizanne, Richardson, Penny, Senior, Peter, Umrania, Yagnesh, Wong, Henna, Burchell, Brendan, Gallacher, John, Murphy, Gavin, Newland, Adrian C, Wheatley, Keith, Greaves, Michael, Turner, Marc, Aziz, Tahir, Brain, Richard, Davies, Christine, Turner, Ruth, Wakeman, Paula, Dent, Alison, Wakeman, Alan, Anthony, Ben, Bland, Desmond, Parrondo, Willem H, Vincent, Helen, Weatherill, Candy, Forsyth, Andrea, Butterfield, Carol, Wright, Tracey, Ellis, Karen, Johnston, Kristie, Poynton, Pat, Brooks, Carolyn, Martin, Emma, Littler, Lara, Williamson, Lindsay, Blair, Donna, Ackerley, Karen, Woods, Lynn, Stanley, Sophie, Walsh, Gemma, Franklin, Gayle, Howath, Cheryl, Sharpe, Sarah, Smith, Deborah, Botham, Lauren, Williams, Caroline, Alexander, Claire, Sowerbutts, Gareth, Furnival, Diane, Thake, Michael, Patel, Shilpa, Roost, Carolyn, Sowerby, Sandra, Appleton, Mary Joy, Bays, Eileen, Bowyer, Geoff, Clarkson, Steven, Halson, Stuart, Holmes, Kate, Humphreys, Gareth, Parvin-Cooper, Lee, Towler, Jason, Addy, Joanne, Barrass, Patrica, Stennett, Louise, Burton, Susan, Dingwell, Hannah, Clarke, Victoria, Potton, Maria, Bolton, Thomas, Daynes, Michael, Spackman, Sarah, Walker, Michael, Momodu, Abudu, Fenton, James, King, Adam, Muhammad, Omer, Oates, Nicholas, Peakman, Tim, Ryan, Christine, Spreckley, Kristian, Stubbins, Craig, Williams, Joanna, Brannan, James, Mochon, Cedric, Taylor, Samantha, Warren, Kimberly, and Mant, Jonathan

Published
2019
Full Text
View/download PDF

14. Diagnosing the NHS

Author

Griffiths, David, Bostock, Rosanne, Wheatley, Keith, and Cockayne, David

Subjects
Literature/writing, Political science
Abstract

Andrew Marr (Politics, 26 May) is concerned we 'may be talking ourselves into an almost terminal depression' about the NHS, but goes on to say it has 'taken so much [...]

Published
2023

15. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors

Author

Di Angelantonio, Emanuele, Thompson, Simon G, Kaptoge, Stephen, Moore, Carmel, Walker, Matthew, Armitage, Jane, Ouwehand, Willem H, Roberts, David J, Danesh, John, Donovan, Jenny, Ford, Ian, Henry, Rachel, Hunt, Beverley J, Le Huray, Bridget, Mehenny, Susan, Miflin, Gail, Green, Jane, Stredder, Mike, Watkins, Nicholas A, McDermott, Alan, Ronaldson, Clive, Thomson, Claire, Tolkien, Zoe, Williamson, Lorna, Allen, David, Sambrook, Jennifer, Hammerton, Tracey, Bruce, David, Choudry, Fizzah, Ghevaert, Cedric, Johnston, Kirstie, Kelly, Anne, King, Andrew, Mo, Alfred, Page, Lizanne, Richardson, Penny, Senior, Peter, Umrania, Yagnesh, Wong, Henna, Murphy, Gavin, Newland, Adrian C, Wheatley, Keith, Greaves, Michael, Turner, Marc, Aziz, Tahir, Brain, Richard, Davies, Christine, Turner, Ruth, Wakeman, Paula, Dent, Alison, Wakeman, Alan, Anthony, Ben, Bland, Desmond, Parrondo, Will, Vincent, Helen, Weatherill, Candy, Forsyth, Andrea, Butterfield, Carol, Wright, Tracey, Ellis, Karen, Poynton, Pat, Brooks, Carolyn, Martin, Emma, Littler, Lara, Williams, Lindsay, Blair, Donna, Ackerley, Karen, Woods, Lynn, Stanley, Sophie, Walsh, Gemma, Franklin, Gayle, Howath, Cheryl, Sharpe, Sarah, Smith, Deborah, Botham, Lauren, Williams, Caroline, Alexander, Claire, Sowerbutts, Gareth, Furnival, Diane, Thake, Michael, Patel, Shilpa, Roost, Carolyn, Sowerby, Sandra, Appleton, Mary Joy, Bays, Eileen, Bowyer, Geoff, Clarkson, Steven, Halson, Stuart, Holmes, Kate, Humphries, Gareth, Parvin-Cooper, Lee, Towler, Jason, Addy, Joanne, Barrass, Patricia, Stennett, Louise, Burton, Susan, Dingwall, Hannah, Clarke, Victoria, Potton, Maria, Bolton, Thomas, Daynes, Michael, Spackman, Sarah, Momodu, Abudu, Fenton, James, King, Adam, Muhammed, Omer, Oates, Nicholas, Peakman, Tim, Ryan, Christine, Spreckley, Kristian, Stubbins, Craig, Williams, Joanna, Brennan, James, Mochon, Cedric, Taylor, Samantha, Warren, Kimberley, and Mant, Jonathan

Published
2017
Full Text
View/download PDF

16. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis

Author

Bufalino, Rosaria, Cameron, David, Cascinelli, Natale, Doherty, Valerie, Eggermont, Alexander, Garbe, Claus, Gore, Martin, Hancock, Barry, Harrison, Rebecca, Ives, Natalie, Kirkwood, John, Kressig, Michael, Lee, Sandra, Lorigan, Paul, MacKie, Rona, Markovic, Svetomir N., Marsden, Jerry, Suciu, Stefan, Suman, Vera, Turner, Lesley, Wheatley, Keith, Ives, Natalie J., and Eggermont, Alexander M.M.

Published
2017
Full Text
View/download PDF

17. Supplementary Data from Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Author

Craddock, Charles F., primary, Houlton, Aimee E., primary, Quek, Lynn Swun, primary, Ferguson, Paul, primary, Gbandi, Emma, primary, Roberts, Corran, primary, Metzner, Marlen, primary, Garcia-Martin, Natalia, primary, Kennedy, Alison, primary, Hamblin, Angela, primary, Raghavan, Manoj, primary, Nagra, Sandeep, primary, Dudley, Louise, primary, Wheatley, Keith, primary, McMullin, Mary Frances, primary, Pillai, Srinivas P., primary, Kelly, Richard J., primary, Siddique, Shamyla, primary, Dennis, Michael, primary, Cavenagh, Jamie D., primary, and Vyas, Paresh, primary

Published
2023
Full Text
View/download PDF

18. Supplemental Table 3 from Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Author

Craddock, Charles F., primary, Houlton, Aimee E., primary, Quek, Lynn Swun, primary, Ferguson, Paul, primary, Gbandi, Emma, primary, Roberts, Corran, primary, Metzner, Marlen, primary, Garcia-Martin, Natalia, primary, Kennedy, Alison, primary, Hamblin, Angela, primary, Raghavan, Manoj, primary, Nagra, Sandeep, primary, Dudley, Louise, primary, Wheatley, Keith, primary, McMullin, Mary Frances, primary, Pillai, Srinivas P., primary, Kelly, Richard J., primary, Siddique, Shamyla, primary, Dennis, Michael, primary, Cavenagh, Jamie D., primary, and Vyas, Paresh, primary

Published
2023
Full Text
View/download PDF

19. Supplemental Table 1 from Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Author

Craddock, Charles F., primary, Houlton, Aimee E., primary, Quek, Lynn Swun, primary, Ferguson, Paul, primary, Gbandi, Emma, primary, Roberts, Corran, primary, Metzner, Marlen, primary, Garcia-Martin, Natalia, primary, Kennedy, Alison, primary, Hamblin, Angela, primary, Raghavan, Manoj, primary, Nagra, Sandeep, primary, Dudley, Louise, primary, Wheatley, Keith, primary, McMullin, Mary Frances, primary, Pillai, Srinivas P., primary, Kelly, Richard J., primary, Siddique, Shamyla, primary, Dennis, Michael, primary, Cavenagh, Jamie D., primary, and Vyas, Paresh, primary

Published
2023
Full Text
View/download PDF

20. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol

Author

Anderton, Jennifer, Moroz, Veronica, Marec-Bérard, Perrine, Gaspar, Nathalie, Laurence, Valerie, Martín-Broto, Javier, Sastre, Ana, Gelderblom, Hans, Owens, Cormac, Kaiser, Sophie, Fernández-Pinto, Melissa, Fenwick, Nicola, Evans, Abigail, Strauss, Sandra, Whelan, Jeremy, Wheatley, Keith, and Brennan, Bernadette

Published
2020
Full Text
View/download PDF

23. Cardiac structure and function after revascularization versus medical therapy for renal artery stenosis: the ASTRAL heart echocardiographic sub-study

Author

Green, Darren, Vassallo, Diana, Handley, Kelly, Ives, Natalie, Wheatley, Keith, Chrysochou, Constantina, Hegarty, Janet, Wright, Julian, Moss, Jon, Patel, Rajan K., Deighan, Chris, Webster, John, Rowe, Peter, Carr, Sue, Cross, Jenny, O’Driscoll, Jamie, Sharma, Raj, Mark, Patrick, and Kalra, Philip A.

Published
2019
Full Text
View/download PDF

25. Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

Author

Park, Julie R., primary, Villablanca, Judith G., additional, Hero, Barbara, additional, Kushner, Brian H., additional, Wheatley, Keith, additional, Beiske, Klaus H., additional, Ladenstein, Ruth L., additional, Baruchel, Sylvain, additional, Macy, Margaret E., additional, Moreno, Lucas, additional, Seibel, Nita L., additional, Pearson, Andrew D., additional, Matthay, Katherine K., additional, and Valteau‐Couanet, Dominique, additional

Published
2022
Full Text
View/download PDF

26. Abstract PO010: Molecular characterization of pediatric hepatocellular carcinoma: genomic, methylomic and transcriptomic analysis

Author

Carrillo-Reixach, Juan, primary, del Río-Álvarez, Álvaro, additional, Royo, Laura, additional, Domingo-Sàbat, Montserrat, additional, Alaggio, Rita, additional, de Krijger, Ronald, additional, Vokuhl, Christian, additional, Garrido, Marta, additional, Guerra, Laura, additional, Sábado, Constantino, additional, Hernández, Francisco, additional, López-Santamaría, Manuel, additional, Bajčiová, Viera, additional, Maibach, Rudolf, additional, Childs, Margaret, additional, Czauderna, Piotr, additional, Wheatley, Keith, additional, Kappler, Roland, additional, Cairo, Stefano, additional, Morland, Bruce, additional, Sala, Margarita, additional, Sarrias, Maria Rosa, additional, and Armengol, Carolina, additional

Published
2022
Full Text
View/download PDF

27. Abstract PO011: Proteomic profiling of childhood liver cancer: identification of novel diagnostic and prognostic biomarkers

Author

Del Río-Álvarez, Álvaro, primary, Carrillo-Reixach, Juan, additional, Royo, Laura, additional, Domingo-Sàbat, Montse, additional, Azkargorta, Mikel, additional, Kapler, Roland, additional, Cairo, Stefano, additional, Vokuhl, Christian, additional, de Krijger, Ronald, additional, Alaggio, Rita, additional, Garrido, Marta, additional, Guillen, Gabriela, additional, Sábado, Constantino, additional, Guerra, Laura, additional, Hernandez, Francisco, additional, Mateos, Maria Elena, additional, López-Satamaría, Manuel, additional, Torres, Barbara, additional, Abad, Maria Pilar, additional, Viera, Bajčiová, additional, Czauderna, Piotr, additional, Buendia, Marie Annick, additional, Elortza, Felix, additional, Wheatley, Keith, additional, Morland, Bruce, additional, and Armengol, Carolina, additional

Published
2022
Full Text
View/download PDF

28. Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)

Author

Hasan, Zeeshaan-Ul, primary, Ahmed, Ikhlaaq, additional, Matin, Rubeta N., additional, Homer, Victoria, additional, Lear, John T., additional, Ismail, Ferina, additional, Whitmarsh, Tristan, additional, Green, Adele C., additional, Thomson, Jason, additional, Milligan, Alan, additional, Hogan, Sarah, additional, Van-de-Velde, Vanessa, additional, Mitchell-Worsford, Liza, additional, Kentley, Jonathan, additional, Gaunt, Claire, additional, Jefferson-Hulme, Yolande, additional, Bowden, Sarah J., additional, Gaunt, Piers, additional, Wheatley, Keith, additional, Proby, Charlotte M., additional, and Harwood, Catherine A., additional

Published
2022
Full Text
View/download PDF

29. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT

Author

Jayne, David, primary, Walsh, Michael, additional, Merkel, Peter A, additional, Peh, Chen Au, additional, Szpirt, Wladimir, additional, Puéchal, Xavier, additional, Fujimoto, Shouichi, additional, Hawley, Carmel, additional, Khalidi, Nader, additional, Jones, Rachel, additional, Flossmann, Oliver, additional, Wald, Ron, additional, Girard, Louis, additional, Levin, Adeera, additional, Gregorini, Gina, additional, Harper, Lorraine, additional, Clark, William, additional, Pagnoux, Christian, additional, Specks, Ulrich, additional, Smyth, Lucy, additional, Ito-Ihara, Toshiko, additional, de Zoysa, Janak, additional, Brezina, Biljana, additional, Mazzetti, Andrea, additional, McAlear, Carol A, additional, Reidlinger, Donna, additional, Mehta, Samir, additional, Ives, Natalie, additional, Brettell, Elizabeth A, additional, Jarrett, Hugh, additional, Wheatley, Keith, additional, Broadhurst, Elizabeth, additional, Casian, Alina, additional, and Pusey, Charles D, additional

Published
2022
Full Text
View/download PDF

32. Reply to R. Lakhotia et al

Author

Burke, G.A. Amos, primary, Minard-Colin, Veronique, additional, Aupérin, Anne, additional, Alexander, Sarah, additional, Pillon, Marta, additional, Delgado, Rafael, additional, Zsíros, József, additional, Uyttebroeck, Anne, additional, Dartigues, Peggy, additional, Miles, Rodney R., additional, Kazanowska, Bernarda, additional, Chiang, Alan K., additional, Haouy, Stéphanie, additional, Bollard, Catherine M., additional, Csoka, Monika, additional, Wheatley, Keith, additional, Barkauskas, Donald A., additional, Adamson, Peter C., additional, Vassal, Gilles, additional, Patte, Catherine, additional, and Gross, Thomas G., additional

Published
2022
Full Text
View/download PDF

33. Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).

Author

McCabe, Martin, primary, Kirton, Laura, additional, Khan, Maria, additional, Fenwick, Nicola, additional, Strauss, Sandra J., additional, Valverde, Claudia, additional, Mata, Cristina, additional, Gaspar, Nathalie, additional, Luksch, Roberto, additional, Longhi, Alessandra, additional, Dirksen, Uta, additional, Phillips, Marianne, additional, Safwat, Akmal, additional, Gelderblom, Hans, additional, Kuehne, Thomas, additional, Kanerva, Jukka, additional, Westwood, Andrew J., additional, Ferrari, Stefano, additional, Whelan, Jeremy, additional, and Wheatley, Keith, additional

Published
2022
Full Text
View/download PDF

34. BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.

Author

Gray, Juliet, primary, Moreno, Lucas, additional, Weston, Rebekah, additional, Barone, Giuseppe, additional, Rubio, Alba, additional, Makin, Guy, additional, Vaidya, Sucheta, additional, Ng, Antony, additional, Castel, Victoria, additional, Nysom, Karsten, additional, Laureys, Genevieve, additional, Van Eijkelenburg, Natasha, additional, Owens, Cormac, additional, Gambart, Marion, additional, Pearson, Andrew DJ, additional, Laidler, Jennifer, additional, Kearns, Pamela, additional, and Wheatley, Keith, additional

Published
2022
Full Text
View/download PDF

35. Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma: A BEACON-Neuroblastoma biomarker study.

Author

Moreno, Lucas, primary, Weston, Rebekah, additional, Viprey, Virginie, additional, Tchirkov, Andrei, additional, Corrias, Maria, additional, Lammens, Tim, additional, Gray, Juliet, additional, Owens, Cormac, additional, Laidler, Jennifer, additional, Gambart, Marion, additional, Castel, Victoria, additional, Van Eijkelenburg, Natasha, additional, Nysom, Karsten, additional, Laureys, Genevieve, additional, Castellano, Aurora, additional, Gerber, Nicolas U., additional, Ladenstein, Ruth Lydia, additional, Valteau Couanet, Dominique, additional, Wheatley, Keith, additional, and Burchill, Susan A, additional

Published
2022
Full Text
View/download PDF

40. Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in Parkinson’s disease

Author

McIntosh, Emma, Kent, Seamus, Gray, Alastair, Clarke, Carl E., Williams, Adrian, Jenkinson, Crispin, Ives, Natalie, Patel, Smitaa, Rick, Caroline, Wheatley, Keith, and Gray, Richard

Subjects
nervous system diseases
Abstract

Background: \ud The PD MED study reported small but persistent benefits in patient‐rated mobility scores and quality of life from initiating therapy with levodopa compared with levodopa‐sparing therapies in early Parkinson's disease (PD).\ud \ud Objectives: \ud The objective was to estimate the cost‐effectiveness of levodopa‐sparing therapy (dopamine agonists or monoamine oxidase type B inhibitors compared with levodopa alone.\ud \ud Methods: \ud PD MED is a pragmatic, open‐label randomized, controlled trial in which patients newly diagnosed with PD were randomly assigned between levodopa‐sparing therapy (dopamine agonists or monoamine oxidase type B inhibitors ) and levodopa alone. Mean quality‐adjusted life‐years and costs were calculated for each participant. Differences in mean quality‐adjusted life‐years and costs between levodopa and levodopa‐sparing therapies and between dopamine agonists and monoamine oxidase type B inhibitors were estimated using linear regression.\ud \ud Results: \ud Over a mean observation period of 4 years, levodopa was associated with significantly higher quality‐adjusted life‐years (difference, 0.18; 95% CI, 0.05–0.30; P

Published
2021

41. Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial

Author

Burke, G. A. Amos, primary, Minard-Colin, Veronique, additional, Aupérin, Anne, additional, Alexander, Sarah, additional, Pillon, Marta, additional, Delgado, Rafael, additional, Zsíros, József, additional, Uyttebroeck, Anne, additional, Dartigues, Peggy, additional, Miles, Rodney R., additional, Kazanowska, Bernarda, additional, Chiang, Alan K., additional, Haouy, Stéphanie, additional, Bollard, Catherine M., additional, Csoka, Monika, additional, Wheatley, Keith, additional, Barkauskas, Donald A., additional, Adamson, Peter C., additional, Vassal, Gilles, additional, Patte, Catherine, additional, and Gross, Thomas G., additional

Published
2021
Full Text
View/download PDF

42. Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial

Author

Chaganti, Sridhar, primary, Maycock, Shanna, additional, McIlroy, Graham, additional, Iqbal, Waleed A, additional, Mason, John, additional, Kanfer, Edward, additional, Kassam, Shireen, additional, Cwynarski, Kate, additional, Wrench, David, additional, Arumainathan, Arvind K., additional, Fox, Christopher P, additional, Johnson, Rod, additional, McKay, Pam, additional, Paneesha, Shankara, additional, Rowntree, Clare J, additional, Balotis, Constantine-George, additional, Collins, Graham P., additional, Davies, Andrew, additional, Wright, Josh, additional, Wheatley, Keith, additional, and Menne, Tobias F, additional

Published
2021
Full Text
View/download PDF

43. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial

Author

Defachelles, Anne-Sophie, primary, Bogart, Emilie, additional, Casanova, Michela, additional, Merks, Johannes H. M., additional, Bisogno, Gianni, additional, Calareso, Giuseppina, additional, Gallego Melcon, Soledad, additional, Gatz, Susanne Andrea, additional, Le Deley, Marie-Cécile, additional, McHugh, Kieran, additional, Probst, Alicia, additional, Rocourt, Nathalie, additional, van Rijn, Rick R., additional, Wheatley, Keith, additional, Minard-Colin, Véronique, additional, and Chisholm, Julia C., additional

Published
2021
Full Text
View/download PDF

47. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA

Author

Burnett, Alan K., Hills, Robert K., Green, Claire, Jenkinson, Sarah, Koo, Kenneth, Patel, Yashma, Guy, Carol, Gilkes, Amanda, Milligan, Donald W., Goldstone, Anthony H., Prentice, Archibald G., Wheatley, Keith, Linch, David C., and Gale, Rosemary E.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results